Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Status:
Withdrawn
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two
antibodies, veltuzumab and epratuzumab. For treatment, epratuzumab has also been attached to
a radioactive isotope called 90yttrium (90Y-epratuzumab). Veltuzumab and 90Y-epratuzumab
attack different areas on lymphoma cells. Because of this, treatment with the combination may
provide more effective treatment in NHL than either veltuzumab or 90Y-epratuzumab given
alone.